


- 133
cancel
- Q1
Sub
P21
9. The peptide display library of claim 8 wherein the peptide comprises lys+/arg+.
 10. The peptide display library of claim 8 wherein the peptide comprises a clone 20-6 peptide.
 11. The process of claim 1 further comprising: selecting a phage resistant to inactivation and determining peptide-protein interactions using the selected phage.
 12. The process of claim 11 wherein the selected phage is affinity purified.
 13. The process of claim 11 wherein the protein's sequence is determined.
 14. A peptide specific for drug delivery, comprising: selecting a drug delivery peptide using the process of claim 1.
 15. The drug delivery peptide of claim 14 wherein the peptide contains a carboxy terminal amino acid selected from the group consisting of arginine and lysine.
 16. The drug delivery peptide of claim 14 containing a tyrosine.
-

REMARKS

Applicant's request that the submitted claims be added to the specification. The claims do not contain new matter.

Respectfully submitted,


Mark K. Johnson Reg. No. 35,909
P.O. Box 510644
New Berlin, WI 53151-0644
(262) 821-5690

I hereby certify that this correspondence is being deposited with the United States Postal Service as EXPRESS MAIL - POST OFFICE TO ADDRESSEE, in an envelope addressed to: Commissioner for Patents, Box Non Fee Amendment, Washington, DC 20231 on 11/15/00.

